Significance of serial beta 2 microglobulin levels in patients of myeloma following high dose treatment and interferon maintenance

被引：0
|
作者：
Raje, N [1 ]
Powles, R [1 ]
Milan, S [1 ]
Horton, C [1 ]
Mehta, J [1 ]
Singhal, S [1 ]
Treleaven, J [1 ]
Cunningham, D [1 ]
机构：
[1] ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1996年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：498 / 498
页数：1
相关论文
共 50 条
  • [21] Interferon (IFN) maintenance treatment following high dose therapy (HDT) in multiple myeloma (MM): side effects, influences on quality of life and acceptance.
    Imbach, U
    Keller, M
    Ho, AD
    Goldschmidt, H
    PSYCHO-ONCOLOGY, 2001, 10 (04) : S71 - S71
  • [22] CLINICAL-SIGNIFICANCE OF BETA-2-MICROGLOBULIN IN DIALYSIS PATIENTS
    STEIN, G
    CARLSOHN, H
    SCHAEFER, K
    ABENDROTH, K
    MARZOLL, I
    SPERSCHNEIDER, H
    GUNTHER, K
    WESSEL, G
    ZEITSCHRIFT FUR UROLOGIE UND NEPHROLOGIE, 1989, 82 (05): : 265 - 272
  • [23] The Prognostic Significance of Beta2 Microglobulin in Patients with Hemophagocytic Lymphohistiocytosis
    Jiang, Tiantong
    Ding, Xiurong
    Lu, Weixing
    DISEASE MARKERS, 2016, 2016
  • [24] Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study
    Feyler, Sylvia
    Rawstron, Andy
    Jackson, Graham
    Snowden, John A.
    Cocks, Kim
    Johnson, Roderick J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (03) : 429 - 433
  • [25] Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study.
    Feyler, S
    Jackson, G
    Rawstron, A
    El-Sherbiny, YM
    Snowden, JA
    Johnson, RJ
    BLOOD, 2003, 102 (11) : 691A - 691A
  • [26] The relationship between glycemic control, beta2-microglobulin and inflammation in patients on maintenance dialysis treatment
    Raikou V.D.
    Kyriaki D.
    Journal of Diabetes & Metabolic Disorders, 14 (1):
  • [27] Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study.
    Feyler, S
    Rawstron, A
    Jackson, G
    Snowden, J
    Hawkins, K
    Johnson, RJ
    BLOOD, 2005, 106 (11) : 190A - 190A
  • [28] SERUM FERRITIN AND BETA-2-MICROGLOBULIN IN PATIENTS WITH MULTIPLE-MYELOMA
    LINKESCH, W
    LUDWIG, H
    CANCER DETECTION AND PREVENTION, 1983, 6 (1-2): : 297 - 301
  • [29] Predictive Significance of Serum Beta 2-Microglobulin Levels and M-Protein Velocity for Symptomatic Progression of Smoldering Multiple Myeloma
    Muta, Tsuyoshi
    Iida, Shinsuke
    Matsue, Kosei
    Sunami, Kazutaka
    Isoda, Jun
    Harada, Naoko
    Saburi, Yoshio
    Okamura, Seiichi
    Kumagae, Kyouya
    Watanabe, Junichi
    Kuroda, Junya
    Aoki, Kenichi
    Ogawa, Ryosuke
    Miyamoto, Toshihiro
    Akashi, Koichi
    Takamatsu, Yasushi
    BLOOD, 2014, 124 (21)
  • [30] Significance of increased serum levels of beta 2 microglobulin in patients with antiphospholipid antibodies syndrome - Study on 55 cases
    Agache, I
    Eftimie, L
    IMMUNOLOGY 2004: AUTOIMMUNITY, GENETIC AND DEGENERATIVE DISORDERS, MALIGNANCIES, AND TRANSPLANTATION, 2004, : 9 - 12
12345